Abstract: A method of treating or preventing one or both of a bacterial infection or fungal infection of a foot of a subject includes combining a diluent and at least one of a clindamycin solution or an erythromycin solution to form a footbath solution. The method may further include topically administering the footbath solution to the subject. Administering may include contacting with the footbath solution a skin area of the foot of the subject that is infected or suspected to be infected.
Abstract: The present invention relates to a crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]-1H-pyrazole-4-carboxamide (Compound A) monohydrate, and processes for preparation thereof. The crystalline form and compositions thereof are useful in the treatment of MALT-1 related diseases.
Type:
Grant
Filed:
February 20, 2020
Date of Patent:
April 8, 2025
Assignee:
Janssen Pharmaceutica NV
Inventors:
Carina Leys, Kristof Leonard Kimpe, Robert Michael Geertman, Haojuan Wei, Peng Zhou
Abstract: Disclosed herein are methods, pharmaceutical combinations, or kits for the prevention or treatment of extrapyramidal syndromes, for example, dyskinesia, dystonia, akathisia, or drug-induced Parkinsonism, with the administration of a therapeutic effective amount of Trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof.
Abstract: Methods for treating pruritis in humans and animals using topically administrable compositions containing olopatadine are disclosed. The compositions quickly relieve itchy skin.
Abstract: The present invention relates to treatment of chronic kidney disease by administering to patients in need thereof a compound of formula (1): and pharmaceutically acceptable salts thereof, wherein Cy, R1 and R2 are as defined herein. The invention further relates to the use of the compounds of formula (1) in combination with sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Type:
Grant
Filed:
December 13, 2022
Date of Patent:
April 1, 2025
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Lisa V. Cronin, Sibylle Jenny Hauske, Hartmut Ruetten
Abstract: Disclosed herein are methods of treating one or more tumors by administering to the subject a therapeutically effective amount of a combination of RAD1901 or solvates (e.g., hydrate) or salts thereof and one or more second therapeutic agent(s) (e.g., everolimus). The cancer is an estrogen-dependent cancer, such as breast cancer, ovarian cancer, colon cancer, endometrial cancer, or prostate cancer.
Abstract: The present invention relates to discloses a pharmaceutical composition of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide and a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
September 14, 2021
Date of Patent:
March 25, 2025
Assignee:
COLUCID PHARMACEUTICALS, INC.
Inventors:
Alison Pilgrim, James F. White, Nadia M. J. Rupniak
Abstract: The present invention relates to a composition comprising a naphthoquinone-based compound as an active ingredient, for preventing or ameliorating fatigue, cachexia, pain, cognitive decline, and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment.
Type:
Grant
Filed:
April 28, 2017
Date of Patent:
March 25, 2025
Assignee:
NADIANBIO Ltd.
Inventors:
Hong Seob So, Hyung-Jin Kim, Gi-Su Oh, Seunghoon Lee, Dipendra Khadka
Abstract: This disclosure provides multifunctional conjugate molecules in which at least one ?-lactam antibiotic is covalently attached to a cannabinoid by means of a linker. The disclosed conjugate molecules are designed to deliver therapeutic benefits as intact molecules, with release of the cannabinoid upon binding of the ?-lactam antibiotic to its target conveying further therapeutic benefits, and can be used to treat bacterial infections and other disorders.
Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins for the treatment of diabetes mellitus. Also described are specific covalent inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the described compounds. Methods of using the menin-MLL covalent inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of diabetes mellitus.
Abstract: Crystalline Forms of Compound (I): pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.
Type:
Grant
Filed:
December 8, 2022
Date of Patent:
March 18, 2025
Assignee:
Blueprint Medicines Corporation
Inventors:
Brenton Mar, Anthony L. Boral, Hui-Min Lin, Hongliang Shi
Abstract: Provided herein are compounds of Formula (I). The compounds described herein are useful in treating a disease associated with the expression of endogenous embryonic/fetal globin (e.g., ? globin) in erythrocytes (e.g., treating ?-thalassemia and/or sickle cell disease through at least the induction of the globin gene expression in erythrocytes), and/or anemia (?-thalassemia and/or sickle cell anemia). The compounds described herein are useful in treating, delaying, and/or preventing the adverse effects of ?-thalassemia and/or sickle cell disease, inducing ? globin production, and/or inducing the expression of embryonic/fetal globin genes in a subject, cell, tissue, or biological sample. Also provided in the present disclosure are pharmaceutical compositions, kits, and methods of using the compounds for inducing ? globin production described herein and for treating any of the target diseases described herein.
Type:
Grant
Filed:
March 25, 2020
Date of Patent:
March 11, 2025
Assignees:
Academia Sinica, National Health Research Institutes
Abstract: This invention relates to compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use these compounds, for example in a method of treatment of cardiac conditions.
Type:
Grant
Filed:
December 4, 2019
Date of Patent:
March 11, 2025
Assignee:
Imperial College Innovations Limited
Inventors:
Michael Schneider, Gary Newton, Kathryn Chapman, Ashley Jarvis, Rehan Aqil, Tifelle Reisinger, Melanie Bayford, Nicholas Chapman, Nicholas Martin, David Middlemiss
Abstract: The present invention includes a method for the use of N-acetylcysteine amide (NACA) or (2R,2R?)-3,3?-disulfanediyl bis(2-acetamidopropanamide) (diNACA) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis (CF), chronic obstructive pulmonary disease (COPD), or bronchitis in a human that comprises administering to the human a therapeutically effective amount of NACA or diNACA sufficient to treat, reduce the symptoms, or prevent radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis (CF), chronic obstructive pulmonary disease (COPD), bronchitis, or respiratory disorder due to oxidative stress, and diNACA for the reduction of mucus viscosity and/or elasticity.
Abstract: The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in medicine.
Abstract: Bacterial species and the associated microbiome persist in tumors and metastases. Antibiotic treatment selectively reduces microbiome-induced tumor growth and can advantageously be included in treatment regimens. Accordingly, the present disclosure relates to, for example, the diagnosing cancer in a subject and providing identifying an effective treatment regimen for the subject.
Abstract: Disclosed are compositions and methods for treating benzodiazepine misuse and/or use disorder. A method of treating benzodiazepine misuse and/or use disorder includes administering to a subject in need thereof of an effective amount of a compound provides both partial modulator and antagonist effects at GABAA receptors.
Type:
Grant
Filed:
June 29, 2021
Date of Patent:
February 25, 2025
Assignee:
UNIVERSITY OF MISSISSIPPI MEDICAL CENTER
Abstract: Disclosed herein are compositions for treating cancer comprising a modified veratridine. In certain aspects, the modified veratridine comprises a polyglutamic acid (PLE) or polyethylene glycol/polyglutamic acid (PEG-PLE) conjugated to the 4? hemiketal thereof. Further disclosed is a method of treating colorectal cancer in a subject comprising administering to a subject an effective amount of the disclosed compositions.
Abstract: Compounds of general formula: wherein R0A and R0B are independently selected from hydrogen and pharmaceutically acceptable cations; and RA and RB are identical and selected from amide, carbamate, sulphonamide, azido, cyano and halide. Also, a pharmaceutical composition including one of the compounds. The composition may also include another active ingredient, especially an antineoplastic agent. Further a compound or a composition for use as a medicament, especially a compound or a composition for use in the treatment of a proliferative disease such as for example cancer.
Type:
Grant
Filed:
November 22, 2019
Date of Patent:
February 25, 2025
Assignees:
UNIVERSITÉ DE NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DU MANS
Inventors:
Fabrice Fleury, Alexandre Demeyer, Pierre Weigel, Benoit Chenais, Monique Mathé, Jacques Lebreton